Hemodynamic and metabolic effects of selective beta1 adrenergic blockade during sepsis
- PMID: 16701103
- DOI: 10.1016/j.surg.2005.10.010
Hemodynamic and metabolic effects of selective beta1 adrenergic blockade during sepsis
Abstract
Background: Selective beta adrenergic antagonists are commonly used to reduce myocardial demise in patients at risk for cardiac-related death. The purpose of this study was to examine the hemodynamic and metabolic effects of cardiac selective beta adrenergic blockade in patients.
Methods: Muscle protein kinetics were quantified using isotopic tracer methodology in 6 moderately septic, mechanically ventilated patients with pneumonia before and then at the conclusion of a 3-hour infusion of esmolol of sufficient dose to reduce heart rate by 20% from baseline. A battery of hemodynamic measurements as facilitated by a thermodilution pulmonary artery catheter and indirect calorimetry were also measured before and after the 3-hour selective beta adrenergic blockade.
Results: Selective beta adrenergic blockade was associated with the 20% reduction in heart rate and a comparable decrease in cardiac output. Esmolol administration failed to affect systemic or pulmonary vascular resistance, oxygen consumption, hepatic or leg blood flow, energy expenditure, or ATP availability/energy charge within muscle. Esmolol infuse did incite a shift in fuel oxidation toward an increase in palmitate oxidation and with a decrease in the oxidation of glucose. There was no demonstrable influence beta1 adrenergic blockade on muscle protein kinetics.
Conclusions: Cardiac selective beta adrenergic blockade with esmolol reduces cardiac output in proportion to the percentage decreases in heart rate in moderately severe septic patients without adversely affecting oxygen utilization or hepatic, peripheral blood flow.
Similar articles
-
Cardioprotection, attenuated systemic inflammation, and survival benefit of beta1-adrenoceptor blockade in severe sepsis in rats.Crit Care Med. 2010 Feb;38(2):388-94. doi: 10.1097/CCM.0b013e3181c03dfa. Crit Care Med. 2010. PMID: 19829100
-
[Effects of adrenergic beta-1 antagonists on hemodynamics of severe septic patients].Zhonghua Yi Xue Za Zhi. 2013 Apr 23;93(16):1243-6. Zhonghua Yi Xue Za Zhi. 2013. PMID: 23902616 Chinese.
-
The effects of esmolol and dexmedetomidine on myocardial oxygen consumption during sympathetic stimulation in dogs.J Cardiothorac Vasc Anesth. 2006 Jun;20(3):364-70. doi: 10.1053/j.jvca.2006.01.013. Epub 2006 Apr 5. J Cardiothorac Vasc Anesth. 2006. PMID: 16750737
-
Esmolol hydrochloride: an ultrashort-acting, beta-adrenergic blocking agent.Clin Pharm. 1986 Apr;5(4):288-303. Clin Pharm. 1986. PMID: 2871961 Review.
-
[Esmolol in anesthesiology: pharmacology and indications].Rev Esp Anestesiol Reanim. 1999 Nov;46(9):404-14. Rev Esp Anestesiol Reanim. 1999. PMID: 10613078 Review. Spanish.
Cited by
-
Gut and sublingual microvascular effect of esmolol during septic shock in a porcine model.Crit Care. 2015 Jun 4;19(1):241. doi: 10.1186/s13054-015-0960-3. Crit Care. 2015. PMID: 26041462 Free PMC article.
-
Sepsis-induced myocardial dysfunction: pathophysiology and management.J Intensive Care. 2016 Mar 23;4:22. doi: 10.1186/s40560-016-0148-1. eCollection 2016. J Intensive Care. 2016. PMID: 27011791 Free PMC article. Review.
-
Esmolol Corrects Severe Hypoxemia in Patients with Femoro-Femoral Venoarterial Extracorporeal Life Support for Lung Transplantation.J Extra Corpor Technol. 2016 Sep;48(3):113-121. J Extra Corpor Technol. 2016. PMID: 27729704 Free PMC article.
-
Bench-to-bedside review: Beta-adrenergic modulation in sepsis.Crit Care. 2009;13(5):230. doi: 10.1186/cc8026. Epub 2009 Oct 23. Crit Care. 2009. PMID: 19863760 Free PMC article. Review.
-
Systematic review of use of β-blockers in sepsis.J Anaesthesiol Clin Pharmacol. 2015 Oct-Dec;31(4):460-5. doi: 10.4103/0970-9185.169063. J Anaesthesiol Clin Pharmacol. 2015. PMID: 26702201 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical